Caris’ platform combines data from whole exome sequencing, whole transcriptome sequencing, protein analysis, and proprietary AI models and signatures to improve patient outcomes through advancement of personalized medicine.
According to the company, the partnership will apply Caris’ data and analytics tools, comprehensive molecular tissue and liquid profiling services, and clinical trial enrollment program capabilities across two therapeutic programs initially, with the option for Incyte to expand to four total programs.
“This partnership with Incyte will leverage Caris’ leading molecular science and technology solutions to support Incyte’s oncology research and development efforts,” said David Spetzler, president and chief scientific officer of Caris Life Sciences. “The aggregate strength of our platform, which provides patient level DNA and RNA data both in tissue and blood, may help to better identify and predict patient response to therapy, which in turn may accelerate clinical trial enrollment, optimize clinical positioning and potentially enhance technical and regulatory success.”
Incyte will also leverage Caris’ biomarker-driven patient selection for clinical trials including options to partner on developing companion diagnostics for programs in the partnership.
“Incyte is committed to identifying new treatments for cancer patients using approaches exploring both single agents and combinations of targeted therapies and immunotherapies in areas of high unmet medical need,” said Jeff Jackson, vice president, Translational Sciences at Incyte. “Our partnership with Caris will bring a comprehensive suite of precision medicine capabilities to augment Incyte’s success in developing key programs in our robust oncology portfolio.”
